Press Release: Phase 2 data published in NEJM show potential of frexalimab as high-efficacy therapy in relapsing MS

Phase 2 data published in NEJM show potential of frexalimab as high-efficacy therapy in relapsing MSHigh-dose frexalimab significantly reduced dis...

Related Keywords

Paris ,France General ,France ,Felix Lauscher ,Nathalie Pham ,Eva Schaefer Jansen ,Corentine Driancourt ,Sally Bain ,Timothy Gilbert ,Sandrine Guendoul ,Tarik Elgoutni ,Patrick Vermersch ,Euronext ,Consortium Of Multiple Sclerosis Centers ,Immunext Inc ,Nasdaq ,University Of Lille ,New England Journal ,Multiple Sclerosis Centers ,Multiple Sclerosis Impact Scale ,Multiple Sclerosis ,Systemic Lupus Erythematosus ,Private Securities Litigation Reform Act ,Statement Regarding Forward Looking ,